Literature DB >> 12738034

Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.

Mamunur Rashid1, Philippe Manivet, Hiroaki Nishio, Jaturong Pratuangdejkul, Mazen Rajab, Masaji Ishiguro, Jean Marie Launay, Takafumi Nagatomo.   

Abstract

The aim of the present study was to investigate the binding sites interactions and the selectivity of sarpogrelate to human 5-HT(2) receptor family (5-HT(2A), 5-HT(2B) and 5-HT(2C) receptor subtypes) using molecular modeling. Rhodopsin (RH) crystal structures were used as template to build structural models of the human serotonin-2A and -2C receptors (5-HT(2A)R, 5-HT(2C)R), whereas for 5-HT(2B)R, we used our previously published three-dimensional (3D) models based on bacteriorhodopsin (BR). Sarpogrelate, a novel 5-HT(2)R antagonist, was docked to the receptors. Molecular dynamics (MD) simulations produced the strongest interaction for 5-HT(2A)R/sarpogrelate complex. Upon binding, sarpogrelate constraints aromatic residues network (Trp(3.28), Phe(5.47), Trp(6.48), Phe(6.51), Phe(6.52) in 5-HT(2A)R; Phe(3.35), Phe(6.51), Trp(7.40) in 5-HT(2B)R; Trp(3.28), Phe(3.35), Phe(5.47), Trp(6.48), Phe(6.51), Phe(6.52) in 5-HT(2C)R) in a stacked configuration, preventing activation of the receptor. The models suggest that the structural origin of the selectivity of sarpogrelate to 5-HT(2A)R vs both 5-HT(2B)R and 5-HT(2C)R comes from the following results: (1) The tight interaction between the antagonist and the transmembrane domain (TMD) 3. Asp(3.32) neutralizes the cationic head and interacts simultaneously with carboxylic group hydrogen of the antagonist molecule. (2) Due to steric hindrance, Ser(5.46) (vs Ala(5.46) in 5HT(2B) and 5HT(2C)) prevents sarpogrelate to enter deeply inside the hydrophobic core of the helix bundle and to interact with Pro(5.50). (3) The side chain of Ile(4.56) (vs Ile(4.56) in 5HT(2B)R and Val(4.56) in 5HT(2C)R) constraints sarpogrelate to adjust its position by translating toward the strongly attractive Asp(3.32). These results are in good agreement with binding affinities (pKi) of sarpogrelate for 5-HT(2) receptor family expressed in transfected cell.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738034     DOI: 10.1016/s0024-3205(03)00227-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

1.  Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists.

Authors:  Roberta Galeazzi; Luca Massaccesi; Francesco Piva; Giovanni Principato; Emilioano Laudadio
Journal:  J Mol Model       Date:  2014-02-22       Impact factor: 1.810

2.  The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.

Authors:  Stephen P H Alexander; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Michael Spedding; John A Peters; Anthony J Harmar
Journal:  Br J Pharmacol       Date:  2013-12       Impact factor: 8.739

3.  From molecular details of the interplay between transmembrane helices of the thyrotropin receptor to general aspects of signal transduction in family a G-protein-coupled receptors (GPCRs).

Authors:  Gunnar Kleinau; Inna Hoyer; Annika Kreuchwig; Ann-Karin Haas; Claudia Rutz; Jens Furkert; Catherine L Worth; Gerd Krause; Ralf Schülein
Journal:  J Biol Chem       Date:  2011-05-17       Impact factor: 5.157

4.  Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.

Authors:  K Przyklenk; A L Frelinger; M D Linden; P Whittaker; Y Li; M R Barnard; J Adams; M Morgan; H Al-Shamma; A D Michelson
Journal:  J Thromb Haemost       Date:  2009-11-17       Impact factor: 5.824

Review 5.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

6.  9-Aminomethyl-9,10-dihydroanthracene (AMDA) analogs as structural probes for steric tolerance in 5-HT2A and H1 receptor binding sites.

Authors:  Jitesh R Shah; Philip D Mosier; Srinivas Peddi; Bryan L Roth; Richard B Westkaemper
Journal:  Bioorg Med Chem Lett       Date:  2009-12-23       Impact factor: 2.823

Review 7.  Novel insights on thyroid-stimulating hormone receptor signal transduction.

Authors:  Gunnar Kleinau; Susanne Neumann; Annette Grüters; Heiko Krude; Heike Biebermann
Journal:  Endocr Rev       Date:  2013-05-03       Impact factor: 19.871

Review 8.  Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.

Authors:  Ralph Weber; Hans-Christoph Diener
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

9.  Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans.

Authors:  Jee Sun Min; Doyun Kim; Jung Bae Park; Hyunjin Heo; Soo Hyeon Bae; Jae Hong Seo; Euichaul Oh; Soo Kyung Bae
Journal:  Drug Des Devel Ther       Date:  2016-09-14       Impact factor: 4.162

10.  Inhibition of 5-Hydroxytryptamine Receptor 2B Reduced Vascular Restenosis and Mitigated the β-Arrestin2-Mammalian Target of Rapamycin/p70S6K Pathway.

Authors:  Yahan Liu; Zhipeng Wang; Jing Li; Yiqian Ban; Guangmei Mao; Man Zhang; Mo Wang; Yan Liu; Beilei Zhao; Qiang Shen; Qingbo Xu; Nanping Wang
Journal:  J Am Heart Assoc       Date:  2018-01-30       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.